MedTrace Logo

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors

NCT06834542 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-04-27

No results posted yet for this study

Summary

This study is an early exploration clinical study with one arm. The study consists of two stages, namely the dose escalation stage and the dose extension stage:

Conditions

  • Adult Gynecological Tumors

Interventions

BIOLOGICAL

Autologous tumor infiltrating lymphocyte injection（GT201）

GT201 treatment for advanced gynecological tumors (advanced cervical cancer)

Sponsors & Collaborators

  • Grit Biotechnology

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06834542 on ClinicalTrials.gov